Publikationen, an denen er mitarbeitet Eduardo Castañón Álvarez (10)

2021

  1. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2020

  1. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

    OncoImmunology, Vol. 9, Núm. 1

  2. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

2016

  1. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

    Clinical and Translational Oncology, Vol. 18, Núm. 3, pp. 259-268

2015

  1. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

2014

  1. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications

    Clinical Genitourinary Cancer, Vol. 12, Núm. 2, pp. 87-93

  2. Epidermal growth factor receptor targeting in non-small cell lung cancer: Revisiting different strategies against the same target

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1273-1283